Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy
| Autor: | Reyhan Gürer, Şenay Aydın, Cigdem Ozkara |
|---|---|
| Přispěvatelé: | İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Remission 03 medical and health sciences Epilepsy Young Adult Juvenile myoclonic epilepsy 0302 clinical medicine Sex Factors Pregnancy medicine Humans In patient Retrospective Studies Valproic Acid Dose-Response Relationship Drug business.industry Low dose Myoclonic Epilepsy Juvenile General Medicine Middle Aged medicine.disease Effective dose (pharmacology) Low-dose valproic acid Pregnancy Complications Absence seizure Cross-Sectional Studies Treatment Outcome Neurology lipids (amino acids peptides and proteins) Anticonvulsants Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug Follow-Up Studies |
| Zdroj: | Seizure. 70 |
| ISSN: | 1532-2688 |
| Popis: | Aydin, Senay/0000-0003-4460-9056; OZKARA, CIGDEM/0000-0003-0548-1838 WOS:000480664600009 PubMed ID: 31252363 Purpose: There are conflicting data regarding the drug dose that is sufficient to achieve seizure control as well as the parameters of seizure remission in juvenile myoclonic epilepsy (JME). The present study aimed to identify factors that contribute to seizure control in JME and to evaluate factors associated with JME remission and the efficacy of low-dose valproic acid (VPA) therapy. Methods: This retrospective, cross-sectional study included a total of 215 patients (121 female and 94 male; mean age: 28.03 +/- 8.43 [14-59] years) diagnosed with JME. The patients were divided into remission and refractory groups. Remission was defined as a seizure-free (myoclonic, absence, and/or generalized tonic-clonic) period of at least 2 years. Patients in whom remission was achieved with VPA monotherapy were further divided into two groups according to the use of low-dose VPA therapy (VPA 750 mg/day). Potential contributing factors were evaluated in terms of the relationship between the dose and the remission parameters. Results: Remission was achieved with VPA monotherapy in 116 patients (87.9%) in the remission group; the VPA dose was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect